This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Talos, F. Articles by Moll, U. M. Search for Related Content PubMed PubMed Citation Articles by Talos, F. Articles by Moll, U. M.

Mitochondrially Targeted p53 Has Tumor Suppressor Activities In vivo

Department of Pathology, Stony Brook University, Stony Brook, New York

Requests for reprints: Ute M. Moll, Department of Pathology, Stony Brook University, Stony Brook, NY 11794-869. Phone: 631-444-2459; Fax: 631-444-3424; E-mail: umoll{at}notes.cc.sunysb.edu.

Complex proapoptotic functions are essential for the tumor suppressor activity of p53. We recently described a novel transcription-independent mechanism that involves a rapid proapoptotic action of p53 at the mitochondria and executes the shortest known circuitry of p53 death signaling. Here, we examine if this p53-dependent mitochondrial program could be exploited for tumor suppression in vivo. To test this, we engage Eµ-Myc transgenic mice, a well-established model of p53-dependent lymphomagenesis. We show that exclusive delivery of p53 to the outer mitochondrial membrane confers a significant growth disadvantage on Eµ-Myc–transformed B-cells of p53-deficient or alternate reading frame–deficient genotypes, resulting in efficient induction of apoptosis and impinged proliferation. Conversely, normal cells from thymus, spleen, and bone marrow showed poor infectivity with these viruses. This proof-of-principle experiment shows that exclusive reliance on the direct mitochondrial program exerts a significant tumor suppressor activity in vivo. Our in vivo data on the direct mitochondrial apoptotic p53 program lays the groundwork to further investigate its efficacy and safety and to address its possible therapeutic value in the future.

This article has been cited by other articles:

				O. Kutuk, E. D. Arisan, T. Tezil, M. C. Shoshan, and H. Basaga Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation Carcinogenesis, September 1, 2009; 30(9): 1517 - 1527. [Abstract] [Full Text] [PDF]

				E. C. Pietsch, E. Perchiniak, A. A. Canutescu, G. Wang, R. L. Dunbrack, and M. E. Murphy Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain J. Biol. Chem., July 25, 2008; 283(30): 21294 - 21304. [Abstract] [Full Text] [PDF]